Risks Discussed for Alternative Peripartum, Neonatal Practices
MONDAY, Jan. 24, 2022 (HealthDay News) — The risks associated with emerging alternative peripartum and neonatal practices are discussed in a report published online Jan. 24 in Pediatrics.Dawn Nolt, M.D., M.P.H., from the Oregon Health and Science Uni…
Learn MoreFrailty Mars Outcomes After aHSCT in Lymphoid Malignancies
MONDAY, Jan. 24, 2022 (HealthDay News) — For patients with lymphoid malignancies undergoing autologous hematopoietic stem cell transplantation (aHSCT), frailty is associated with worse hospital outcomes, according to a study published online Dec. 23 …
Learn MoreMRI of Hand, Foot May Predict RA in Undifferentiated Arthritis
MONDAY, Jan. 24, 2022 (HealthDay News) — Magnetic resonance imaging (MRI) of the hand and foot may predict rheumatoid arthritis (RA) in patients presenting with undifferentiated arthritis (UA), according to a study published online Jan. 12 in Rheumat…
Learn MoreRisk for Cancer Increased After VTE for Patients With Psoriasis
MONDAY, Jan. 24, 2022 (HealthDay News) — For patients with psoriasis, the risk for cancer is increased at the time of or after venous thromboembolism (VTE), according to a research letter published online Jan. 18 in the British Journal of Dermatology…
Learn MoreVaccination, Previous Infection Protect Against COVID-19
MONDAY, Jan. 24, 2022 (HealthDay News) — Vaccination and previous COVID-19 infection were protective against COVID-19 infection and hospitalization during the alpha and delta severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) waves, accord…
Learn MorePandemic Having Major Impact on Pediatric Oncology Providers
MONDAY, Jan. 24, 2022 (HealthDay News) — The COVID-19 pandemic is having a profound impact on pediatric oncology health care providers (HCPs), according to a study published online Jan. 24 in Cancer.Elizabeth R. Sniderman, M.S.N., from St. Jude Child…
Learn MoreCombo Immunotherapy Ups Survival in Advanced Liver Cancer
MONDAY, Jan. 24, 2022 (HealthDay News) — STRIDE (Single tremelimumab Regular Interval durvalumab) is proposed as first-line therapy for unresectable hepatocellular carcinoma (uHCC), according to a study presented at the annual American Society of Cli…
Learn MoreAdding Immunotherapy to Chemo Ups Survival in Advanced Biliary Tract Cancer
MONDAY, Jan. 24, 2022 (HealthDay News) — Adding the immunotherapeutic agent durvalumab to standard chemotherapy improves survival in advanced biliary tract cancer, according to a study presented at the annual American Society of Clinical Oncology Gas…
Learn MoreAd26.COV2.S, mRNA Boosters Immunogenic After Ad26.COV2.S
MONDAY, Jan. 24, 2022 (HealthDay News) — For health care workers who received a priming dose of the Ad26.COV2.S vaccine, Ad26.COV2.S and mRNA boosters are immunogenic, with the strongest responses after boosting with an mRNA-based vaccine, according …
Learn MoreMicrobiome Therapeutic Beats Placebo for Recurrent C. difficile
MONDAY, Jan. 24, 2022 (HealthDay News) — An investigational microbiome therapeutic composed of purified Firmicutes spores, SER-109, is superior to placebo for treatment of recurrent Clostridioides difficile infection, according to a study published i…
Learn More